CTI BioPharma Corp. (CTIC)
(Delayed Data from NSDQ)
$0.99 USD
+0.01 (1.49%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.99 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CTIC 0.99 +0.01(1.49%)
Will CTIC be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CTIC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CTIC
Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates
CTIC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will CTI BioPharma (CTIC) Report Negative Earnings Next Week? What You Should Know
Incyte (INCY) Gets CRL for Jakafi Extended-Release Tablets
CTI BioPharma (CTIC) Reports Q4 Loss, Lags Revenue Estimates